Cargando…

Symptom burden & quality of life among patients receiving second-line treatment of metastatic colorectal cancer

BACKGROUND: Bevacizumab (B) and cetuximab (C) are both approved for use in the treatment of metastatic colorectal cancer (mCRC) in the second-line. We examined patient reported symptom burden during second-line treatment of mCRC. METHODS: Adult mCRC patients treated in the second-line setting with a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Walker, Mark S, Pharm, Elaine Yu, Kerr, Jiandong, Yim, Yeun Mi, Stepanski, Edward J, Schwartzberg, Lee S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3532189/ https://www.ncbi.nlm.nih.gov/pubmed/22716038 http://dx.doi.org/10.1186/1756-0500-5-314

Ejemplares similares

Retrospective study of the effect of disease progression on patient reported outcomes in HER-2 negative metastatic breast cancer patients
por: Walker, Mark S, et al.
Publicado: (2011)

Racial Differences in Patient-Reported Symptoms and Adherence to Adjuvant Endocrine Therapy Among Women With Early-Stage, Hormone Receptor–Positive Breast Cancer
por: Hu, Xin, et al.
Publicado: (2022)

Characterization of Clinical Symptoms by Race Among Women With Early-Stage, Hormone Receptor–Positive Breast Cancer Before Starting Chemotherapy
por: Hu, Xin, et al.
Publicado: (2021)

Biomarkers defining probability of receiving second-line targeted therapy in metastatic renal cell carcinoma
por: Chrom, Pawel, et al.
Publicado: (2018)

XELIRI compared with FOLFIRI as a second-line treatment in patients with metastatic colorectal cancer
por: CUI, CHENGXU, et al.
Publicado: (2014)

Beyond second-line therapy in patients with metastatic colorectal cancer: a systematic review
por: Arnold, D, et al.
Publicado: (2018)

Treatment Patterns in US Patients Receiving First-Line and Second-Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma in the Real World
por: King, Gentry, et al.
Publicado: (2022)

Health-related quality of life in patients receiving first-line eribulin mesylate with or without trastuzumab for locally recurrent or metastatic breast cancer
por: Schwartzberg, Lee, et al.
Publicado: (2019)

Role of free testosterone levels in patients with metastatic castration-resistant prostate cancer receiving second-line therapy
por: von Klot, Christoph A., et al.
Publicado: (2017)

Phase II study of lapatinib in combination with vinorelbine, as first or second-line therapy in women with HER2 overexpressing metastatic breast cancer
por: Chew, Helen Kent, et al.
Publicado: (2014)

Effectiveness of bevacizumab in first- and second-line treatment for metastatic colorectal cancer: ITACa randomized trial
por: Petracci, Elisabetta, et al.
Publicado: (2020)

Metastatic Colorectal Cancer Outcomes by Age Among ARCAD First- and Second-Line Clinical Trials
por: McCleary, Nadine J, et al.
Publicado: (2022)

Prospective Analysis of Patients with Metastatic Breast Cancer receiving Eribulin Mesylate as Second or More Lines of Chemotherapy: An Indian Experience
por: Srinivasa, BJ, et al.
Publicado: (2018)

Predictors for use of psychosocial services in patients with metastatic colorectal cancer receiving first line systemic treatment
por: Schuurhuizen, Claudia S. E. W., et al.
Publicado: (2019)

Phase II Study of Biweekly Pemetrexed Plus Irinotecan as Second-Line Therapy for Metastatic Colorectal Cancer
por: Louvet, C., et al.
Publicado: (2010)

How to Deal with Second Line Dilemma in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis
por: Galvano, Antonio, et al.
Publicado: (2019)

Real-World Treatment Patterns and Outcomes in Patients Receiving Second-Line Therapy for Advanced/Metastatic Esophageal Squamous Cell Carcinoma
por: Abraham, Pranav, et al.
Publicado: (2020)

Second-line chemotherapy after early disease progression during first-line chemotherapy containing bevacizumab for patients with metastatic colorectal cancer
por: Yamamoto, Shun, et al.
Publicado: (2021)

Health-related quality of life in patients with metastatic colorectal cancer treated with panitumumab in first- or second-line treatment
por: Bennett, L, et al.
Publicado: (2011)

Phase I study of FOLFIRI plus pimasertib as second-line treatment for KRAS-mutated metastatic colorectal cancer
por: Macarulla, T, et al.
Publicado: (2015)

Phase II trial of aflibercept with FOLFIRI as a second‐line treatment for Japanese patients with metastatic colorectal cancer
por: Denda, Tadamichi, et al.
Publicado: (2019)

Ramucirumab in the second-line treatment of metastatic colorectal cancer: a narrative review of literature from clinical trials
por: Chen, Chou-Pin, et al.
Publicado: (2020)

Burden of symptoms associated with development of metastatic bone disease in patients with breast cancer
por: Cleeland, Charles, et al.
Publicado: (2016)

Circulating microRNA profile predicts disease progression in patients receiving second-line treatment of lapatinib and capecitabine for metastatic pancreatic cancer
por: TIAN, XUEFEI, et al.
Publicado: (2016)

Skeletal Muscle Mass Reduction Velocity as a Simple Prognostic Indicator for Patients with Metastatic Urothelial Carcinoma Receiving Second-Line Chemotherapy
por: Nagai, Takashi, et al.
Publicado: (2019)

Inflammation-based markers can predict the prognosis of geriatric patients with metastatic colorectal cancer receiving first-line chemotherapy
por: Guo, Guifang, et al.
Publicado: (2019)

Ramucirumab, another anti-angiogenic agent for metastatic colorectal cancer in second-line setting—its impact on clinical practice
por: Goel, Gaurav, et al.
Publicado: (2015)

Folfiri-Aflibercept vs. Folfiri-Bevacizumab as Second Line Treatment of RAS Mutated Metastatic Colorectal Cancer in Real Practice
por: Ottaiano, Alessandro, et al.
Publicado: (2019)

Prognostic Factors of Survival with Aflibercept and FOLFIRI (fluorouracil, leucovorin, irinotecan) as Second-line Therapy for Patients with Metastatic Colorectal Cancer
por: Kim, Jinchul, et al.
Publicado: (2021)

Evidence-Based Second-Line Treatment in RAS Wild-Type/Mutated Metastatic Colorectal Cancer in the Precision Medicine Era
por: Giordano, Guido, et al.
Publicado: (2021)

Aflibercept Plus FOLFIRI as Second-Line Treatment for Metastatic Colorectal Cancer: A Single-Institution Real-Life Experience
por: Lavacchi, Daniele, et al.
Publicado: (2021)

Are All Anti-Angiogenic Drugs the Same in the Treatment of Second-Line Metastatic Colorectal Cancer? Expert Opinion on Clinical Practice
por: Lai, Eleonora, et al.
Publicado: (2021)

Biweekly Raltitrexed Combined With Irinotecan as Second-Line Therapy for Patients With Metastatic Colorectal Cancer: A Phase II Trial
por: Cheng, Ke, et al.
Publicado: (2022)

Outcome and prognostic factors in metastatic urothelial carcinoma patients receiving second-line chemotherapy: an analysis of real-world clinical practice data in Japan
por: Matsumoto, Ryuji, et al.
Publicado: (2018)

Real-world treatment patterns, healthcare resource use and clinical outcomes of patients receiving second line therapy for advanced or metastatic gastric cancer
por: Gómez-Ulloa, David, et al.
Publicado: (2020)

A step-by-step approach to using SAS for univariate & multivariate statistics
por: O'Rourke, Norm, et al.
Publicado: (2005)

Patient‐reported symptom burden as a prognostic factor in treatment with first‐line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer: Results of Phase II QUACK trial
por: Ooki, Akira, et al.
Publicado: (2020)

Aflibercept or bevacizumab in combination with FOLFIRI as second-line treatment of mRAS metastatic colorectal cancer patients: the ARBITRATION study protocol
por: Ottaiano, Alessandro, et al.
Publicado: (2021)

Optimal Sequence and Second-Line Systemic Treatment of Patients with RAS Wild-Type Metastatic Colorectal Cancer: A Meta-Analysis
por: Wu, Chih-Chien, et al.
Publicado: (2021)

Avelumab vs Standard Second-Line Chemotherapy in Patients With Metastatic Colorectal Cancer and Microsatellite Instability: A Randomized Clinical Trial
por: Taïeb, Julien, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_11pstnnl1hs5t2q28iep7fs38n